Cargando…

Lessons From the Development of the Immune Checkpoint Inhibitors in Oncology

Immunotherapies are becoming increasingly important in the treatment armamentarium of a variety of malignancies. Immune checkpoint inhibitors are the most representative drugs receiving regulatory approval over the past few years. In a recent study published in Clinical Cancer Research, we demonstra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jardim, Denis L., de Melo Gagliato, Débora, Kurzrock, Razelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2018
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247554/ https://www.ncbi.nlm.nih.gov/pubmed/30229677 http://dx.doi.org/10.1177/1534735418801524

Ejemplares similares

Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compounds
por: Jardim, Denis L., et al.
Publicado: (2020)

Hyperprogression and Immune Checkpoint Inhibitors: Hype or Progress?
por: Adashek, Jacob J., et al.
Publicado: (2019)

An appraisal of drug development timelines in the Era of precision oncology
por: Jardim, Denis Leonardo, et al.
Publicado: (2016)

Remembering the forgotten child: the role of immune checkpoint inhibition in patients with human immunod eficiency virus and cancer
por: Adashek, Jacob J., et al.
Publicado: (2019)

Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis
por: Xavier, Camila Bragança, et al.
Publicado: (2022)

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology
por: Özdemir, Berna C
Publicado: (2021)

The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match
por: Subbiah, Vivek, et al.
Publicado: (2018)

Angiosarcoma heterogeneity and potential therapeutic vulnerability to immune checkpoint blockade: insights from genomic sequencing
por: Boichard, Amélie, et al.
Publicado: (2020)

Actionability and precision oncology
por: Schwaederle, Maria, et al.
Publicado: (2015)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

The gut microbiota and immune checkpoint inhibitors
por: Humphries, Audrey, et al.
Publicado: (2018)

Immune checkpoint inhibitor-related acral vasculitis
por: Comont, Thibault, et al.
Publicado: (2018)

MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit
por: Jardim, Denis L. Fontes, et al.
Publicado: (2014)

COVID-19 and immune checkpoint inhibitors: initial considerations
por: Sullivan, Ryan J, et al.
Publicado: (2020)

Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer
por: de Melo Gagliato, Debora, et al.
Publicado: (2016)

Gene expression profiles (GEPs) of immuno-oncologic pathways as predictors of response to checkpoint inhibitors in advanced NSCLC
por: De Marchi, Pedro, et al.
Publicado: (2023)

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
por: Tawbi, Hussein A, et al.
Publicado: (2023)

Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer: A Brazilian Center Experience
por: Jardim, Denis Leonardo Fontes, et al.
Publicado: (2012)

Immune checkpoint inhibitors: here to stay
por: Carvalho, Filomena Marino, et al.
Publicado: (2023)

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes
por: Kurzrock, Razelle, et al.
Publicado: (2015)

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches
por: Tojjari, Alireza, et al.
Publicado: (2023)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
por: Akhuba, Liia, et al.
Publicado: (2023)

Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment
por: Rossi, Ernesto, et al.
Publicado: (2020)

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma
por: Ang, Celina, et al.
Publicado: (2019)

Association of immune-related adverse events with immune checkpoint inhibitor efficacy: real or imaginary?
por: Haratani, Koji, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors and Radiotherapy in NSCLC Patients: Not Just a Fluke
por: Belluomini, Lorenzo, et al.
Publicado: (2019)

Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors
por: Bersanelli, Melissa
Publicado: (2020)

How Compatible Are Immune Checkpoint Inhibitors and Thermal Ablation for Liver Metastases?
por: Minami, Yasunori, et al.
Publicado: (2022)

Combining STAT3-Targeting Agents with Immune Checkpoint Inhibitors in NSCLC
por: Papavassiliou, Kostas A., et al.
Publicado: (2023)

Cancer vaccine: learning lessons from immune checkpoint inhibitors
por: Ye, ZhenLong, et al.
Publicado: (2018)

Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma
por: Mohr, Raphael, et al.
Publicado: (2021)

Systemic immune parameters after prior radiation therapy in patients receiving immune checkpoint inhibitors
por: Mundra, Vatsala, et al.
Publicado: (2023)

MET alterations detected in blood-derived circulating tumor DNA correlate with bone metastases and poor prognosis
por: Ikeda, Sadakatsu, et al.
Publicado: (2018)

Immune checkpoint inhibitors and the shared epitope theory: from hypothesis to practice
por: Lerrer, Shalom, et al.
Publicado: (2019)

Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
por: Gupta, Amol, et al.
Publicado: (2023)

Dosing targeted and cytotoxic two‐drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013
por: Nikanjam, Mina, et al.
Publicado: (2016)

Immune checkpoint inhibitor induced neurocognitive deficits in patients
por: Zeiser, Robert, et al.
Publicado: (2023)

Immune checkpoint inhibitors: Advances and impact in neuro-oncology
por: Fares, Jawad, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mckeavpkm3nbj3mspscchfp23s